A popular drug used for diabetes and weight loss may also help protect the brain. That’s the key message from a new study ...

A real-world study found that semaglutide prescriptions were associated with improvements in weight, blood pressure, and ...

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, Wegovy) is not cost-effective at current pricing, new research shows ...

Semaglutide is an injectable drug formulated for the treatment of type 2 diabetes, but it’s since become increasingly popular as a weight loss treatment. While the drug—commonly known by brand ...

The FLOW trial demonstrated that semaglutide significantly improves kidney and cardiovascular outcomes in people with chronic kidney disease and type 2 diabetes, irrespective of SGLT2 inhibitor use.

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389 (24):2221-2232. doi: 10.1056/NEJMoa2307563.

2. Cardiovascular protection Semaglutide has been shown to reduce the risk of major cardiovascular events (such as heart attacks and strokes) in patients with type 2 diabetes.

Semaglutide 2.4mg improved heart failure-related symptoms in patients with heart failure with preserved ejection fraction (HFpEF) and obesity, according to findings from the STEP HFpEF trial ...